Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8524918 | 1.00 | MAPT (0.50) | MAPTALDH1A1KDM4EMAPK1TSHR | |
| SCHEMBL6537862 | 0.89 | APP (0.54) | MAPTALDH1A1KDM4EMAPK1APP | |
| SCHEMBL6537866 | 0.89 | APP (0.54) | MAPTALDH1A1KDM4EMAPK1APP | |
| SCHEMBL6538195 | 0.83 | MAPT (0.70) | MAPTALDH1A1TSHR | |
| SCHEMBL6538193 | 0.83 | MAPT (0.70) | MAPTALDH1A1TSHR | |
| SCHEMBL6537797 | 0.80 | MAPT (0.59) | MAPTALDH1A1MAPK1BACE1 | |
| SCHEMBL8474164 | 0.80 | MAPT (0.59) | MAPTALDH1A1MAPK1BACE1 | |
| SCHEMBL6980498 | 0.79 | MEN1 (0.53) | MAPTALDH1A1KDM4EMAPK1PHGDH | |
| SCHEMBL6980493 | 0.79 | MEN1 (0.53) | MAPTALDH1A1KDM4EMAPK1PHGDH | |
| SCHEMBL27669245 | 0.77 | TSHR (0.53) | MAPTALDH1A1KDM4EMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0876345-B1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-6008230-A | TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0876345-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997014681-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-24 | — | — | WO | disclosed |